MONTRÉAL, September 22, 2022 – Imagia Canexia Health (ICH), a genomics-based cancer testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced that William Annett has joined the company’s Board of Directors. Mr. Annett brings decades of experience in corporate leadership and a long track record of building innovative entrepreneurial life sciences companies in both diagnostics and therapeutics. He served as Chief Executive at seven organizations—including taking two public—as well as holding senior management positions at Accenture and Genentech. He is currently the President and CFO at Sustained Therapeutics, a clinical stage company developing non-opioid treatments for chronic pain. Previously, Mr. Annett was the  CEO of OncoCyte, a precision diagnostics company focused on providing personalized insights to inform critical clinical decisions. He received his MBA from the Harvard Graduate School of Business Administration. 

As ICH continues to develop its vision of combining advanced genomics, oncology, artificial intelligence, and informatics so health systems can offer cost-effective cancer testing in-house, William’s industry expertise will provide ICH guidance in R&D, product development, commercialization, raising capital, and more.

“I share Imagia Canexia Health’s conviction that innovation in precision oncology has tremendous potential for transforming patient care. I am excited about the opportunity to serve on ICH’s Board and support the team’s efforts  to build a company dedicated to broadening access to cutting edge technology, ” said Mr. Annett. “With so much to offer cancer clinics by way of ICH’s liquid biopsy testing and Imagia Canexia Health Insights Platform (ICHIP), we are developing the tools to increase equitable access to cancer testing.”  

“Imagia Canexia Health is focused on scaling our business so that more cancer patients will have access to our suite of cancer testing solutions, and William joining ICH’s board brings the insights to foster our expansion with maximum impact,” said Imagia Canexia Health CEO Geralyn Ochab. “William’s deep operational experiences in biopharma & diagnostics is an incredible addition to our team.”  

 

About Imagia Canexia Health
Imagia Canexia Health (ICH) is a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions. Leveraging AI-based informatics for treatment selection and monitoring, oncologists now have leading clinical decision support right at their fingertips. With a network of over 20 hospitals and reference labs worldwide, ICH ensures that doctors have the right insights to deliver cost-effective cancer testing to patients no matter where they seek treatment. Join ICH in closing the health-equity gap in cancer: imagiacanexiahealth.com 

 

Contact:
Shelley Epstein, Executive Vice-President, Corporate and Public Affairs
Imagia Canexia Health
514-451-6343

Back

Recent Resources

Blog

August 30, 2022

CGC 2022 Key Takeaways

NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting